Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Strayer

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Clinical Oncology|August 1, 1987
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferonsD R Strayer, J Weisband, W A Carter, et al.
Progress in Clinical and Biological Research|January 1, 1985
Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinicallyR J Suhadolnik, N L Reichenbach, C Lee, et al.
Texas Reports on Biology and Medicine|January 1, 1981
Clinical studies with mismatched double-stranded RNAD R Strayer, W A Carter, I Brodsky, et al.
In Vivo (Athens, Greece)|May 1, 1994
Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elementsD Gillespie, H R Hubbell, W A Carter, et al.
International Journal of Immunopharmacology|January 1, 1991
Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV diseaseW A Carter, D Ventura, D E Shapiro, et al.
Annals of the New York Academy of Sciences|June 23, 1993
RNA drug therapy acting via the 2-5A synthetase/RNase L pathwayR J Suhadolnik, N L Reichenbach, P M Hitzges, et al.
Anticancer Research|May 1, 1990
Differential effects of human natural interferon-alpha and mismatched double-stranded RNA against a human renal cell carcinoma xenograftH R Hubbell, E C Pequignot, K R Shanabrook, et al.
Annals of the New York Academy of Sciences|June 23, 1993
Specific RNA drug therapy of hepatitis virusesW A Carter, R J Suhadolnik, W E Müller, et al.
Journal of Biological Response Modifiers|October 1, 1987
Augmented antitumor effect of combined human natural interferon-alpha and mismatched double-stranded RNA treatment against a human malignant melanoma xenograftH R Hubbell, E C Pequignot, J Todd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1994
A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndromeD R Strayer, W A Carter, I Brodsky, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Oncology|August 1, 1987
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferonsD R Strayer, J Weisband, W A Carter, et al.
Progress in Clinical and Biological Research|January 1, 1985
Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinicallyR J Suhadolnik, N L Reichenbach, C Lee, et al.
Texas Reports on Biology and Medicine|January 1, 1981
Clinical studies with mismatched double-stranded RNAD R Strayer, W A Carter, I Brodsky, et al.
In Vivo (Athens, Greece)|May 1, 1994
Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elementsD Gillespie, H R Hubbell, W A Carter, et al.
International Journal of Immunopharmacology|January 1, 1991
Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV diseaseW A Carter, D Ventura, D E Shapiro, et al.
Annals of the New York Academy of Sciences|June 23, 1993
RNA drug therapy acting via the 2-5A synthetase/RNase L pathwayR J Suhadolnik, N L Reichenbach, P M Hitzges, et al.
Anticancer Research|May 1, 1990
Differential effects of human natural interferon-alpha and mismatched double-stranded RNA against a human renal cell carcinoma xenograftH R Hubbell, E C Pequignot, K R Shanabrook, et al.
Annals of the New York Academy of Sciences|June 23, 1993
Specific RNA drug therapy of hepatitis virusesW A Carter, R J Suhadolnik, W E Müller, et al.
Journal of Biological Response Modifiers|October 1, 1987
Augmented antitumor effect of combined human natural interferon-alpha and mismatched double-stranded RNA treatment against a human malignant melanoma xenograftH R Hubbell, E C Pequignot, J Todd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1994
A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndromeD R Strayer, W A Carter, I Brodsky, et al.
Pageof 4